We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Water Vapor Therapy Offers Alterative to Surgery or Radiation for Treating Prostate Cancer

By HospiMedica International staff writers
Posted on 08 Jan 2025

Intermediate-risk prostate cancer, in which the tumor remains confined to the prostate gland and does not spread to other organs, makes up about one-third of all localized prostate cancers. More...

Some individuals with prostate cancer may not require treatment if the tumor is small and slow-growing. However, when treatment is necessary, the standard approach has been surgery or radiation. While these methods are generally effective in treating the cancer, they can also lead to side effects. The prostate is located between the bladder, the urethra (a duct that carries urine from the bladder), and the rectum. It is surrounded by nerves responsible for penile erections and the muscle that controls urine flow, the urinary sphincter. During surgery or radiation, there is a risk of damaging healthy tissue along with the cancer and affecting the delicate structures adjacent to the prostate. The most common side effects of these treatments include impotence, urinary incontinence, and bowel dysfunction. Increasing research suggests that some patients may benefit from a procedure with fewer risks that enables them to maintain a higher quality of life post-treatment.

Steam offers a precise way to deliver heat into the body. Keck Medicine of USC (Los Angeles, CA, USA) is now involved in a U.S.-based, multisite clinical trial to determine whether a water vapor system, which uses small, targeted amounts of steam to destroy cancer cells, is a safe and effective treatment for prostate cancer. Researchers believe that steam may provide a less invasive option for managing or curing cancer compared to current methods. The study is sponsored by Francis Medical (Maple Grove, MN, USA), which developed the Vanquish Water Vapor Ablation System used in the trial. This water vapor ablation system is one of several minimally invasive treatments for prostate cancer that are either currently in use or under development in the field of urology.

Before the procedure, physicians use magnetic resonance imaging (MRI) to locate the tumor cells within the patient's prostate. During the procedure, doctors use ultrasound and prostate mapping to guide a thin catheter through the patient’s urethra into the prostate area containing the tumor. Once the catheter is properly positioned, a fine needle is deployed into the tumor. Doctors then release a brief, targeted 10-second burst of steam from the needle, with additional bursts as needed, to destroy the tumor. This method is believed to be gentler on the body than traditional therapies and is designed to focus on the cancerous tissue within the prostate. Researchers are investigating whether steam can effectively destroy cancer cells without damaging surrounding organs. Another potential benefit of this investigational therapy is that, unlike surgery, which requires an overnight hospital stay, the water vapor therapy is an outpatient procedure. Furthermore, unlike radiation, which typically requires multiple sessions, this water vapor therapy is designed to be effective with just one application.

“The most common therapies for prostate cancer often cause life-altering side effects, and we are investigating if this new treatment may not only treat the cancer, but offer our patients overall better quality-of-life outcomes,” said Andre Abreu, MD, a Keck Medicine urologist and lead investigator of the Keck Medicine clinical trial site. “Over the next decade or so, we hope to see innovative therapies revolutionize how we help patients become cancer-free while maintaining their quality of life.”

Related Links:
Francis Medical 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Open Stapler
PROXIMATE Linear Cutter
New
Ultrasonic Dissector
SONICBEAT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: New clinical guidance suggests treatments to prevent blood clots in CLTI patients after leg artery procedures (Photo courtesy of Shutterstock)

Stronger Blood Clot Prevention Measures Needed After Leg Artery Procedures in High-Risk Patients

Chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease (PAD), significantly reduces blood flow to the legs and feet. Despite undergoing lower limb revascularization... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.